临床误诊误治2024,Vol.37Issue(18) :88-94.DOI:10.3969/j.issn.1002-3429.2024.18.015

杞菊地黄丸联合睑板腺按摩挤压治疗睑板腺功能障碍性干眼症的效果观察

Observation on the Efficacy of Qiju Dihuang Pills Combined with Meibo-mian Gland Massage and Compression in the Treatment of Dry Eye Syn-drome Caused by Meibomian Gland Dysfunction

孙彩英 王春梅 刘化峰 乔玉培 宗瑞琪 贾俊 赵桂霞
临床误诊误治2024,Vol.37Issue(18) :88-94.DOI:10.3969/j.issn.1002-3429.2024.18.015

杞菊地黄丸联合睑板腺按摩挤压治疗睑板腺功能障碍性干眼症的效果观察

Observation on the Efficacy of Qiju Dihuang Pills Combined with Meibo-mian Gland Massage and Compression in the Treatment of Dry Eye Syn-drome Caused by Meibomian Gland Dysfunction

孙彩英 1王春梅 2刘化峰 1乔玉培 3宗瑞琪 3贾俊 3赵桂霞2
扫码查看

作者信息

  • 1. 063300 河北唐山,唐山市丰南区中医医院眼科
  • 2. 063000 河北唐山,唐山市眼科医院中医葡萄膜神经眼科
  • 3. 063000 河北唐山,唐山市眼科医院干眼诊疗中心
  • 折叠

摘要

目的 探讨杞菊地黄丸联合睑板腺按摩挤压治疗睑板腺功能障碍(MGD)性干眼症的效果及对主观症状、泪液炎性因子、生活质量的影响.方法 选取2022 年1 月至2023 年 7 月收治的MGD性干眼症患者 84 例,采用随机数字表法分为观察组、对照组各42 例.2 组均予以常规治疗,对照组在此基础上予以联合睑板腺按摩,观察组在对照组基础上予以杞菊地黄丸,均治疗8 周.比较2 组临床疗效,治疗前后主观症状评分、睑板开口状态评分、睑板腺分泌物性状评分、基础泪液分泌试验(SIT)、角膜荧光染色评分(FLS)、泪膜破裂时间、泪液白细胞介素-10(IL-10)、泪液白细胞介素-13(IL-13)及成纤维细胞生长因子受体 2(FGFR2)表达水平及生活质量,记录 2 组不良反应发生率.结果 2 组均有2 例脱落.观察组治疗总有效率[90.00%(36/40)]高于对照组[72.50%(29/40)],差异有统计学意义(P<0.05);治疗4 及8 周,观察组SIT、泪膜破裂时间长于对照组,主观症状评分、睑板腺功能评分、FLS低于对照组(P<0.01);治疗4 及8 周,观察组泪液IL-10、FGFR2 表达水平高于对照组,IL-13 表达水平低于对照组(P<0.05).2组不良反应发生率比较差异无统计学意义(P>0.05).治疗8 周及12 周,观察组生活质量测定量表简表评分高于对照组(P<0.05).结论 杞菊地黄丸联合睑板腺按摩挤压治疗MGD性干眼症安全有效,可抑制炎症反应,改善临床症状及患者生活质量.

Abstract

Objective To investigate the efficacy of Qiju Dihuang pills combined with meibomian gland massage and compression in the treatment of dry eye syndrome caused by meibomian gland dysfunction(MGD),as well as their impact on subjective symptoms,inflammatory factors in tears,and quality of life.Methods Eighty-four patients with dry eye syndrome caused by MGD from January 2022 to July 2023 were selected and randomly divided into the observation group(n=42)and the control group(n=42).Both groups received conventional treatment.In addition,the control group received combined meibomian gland massage,while the observation group received Qiju Dihuang pills on the basis of the control group's treat-ment.The course of treatment was 8 weeks for both groups.The clinical efficacy of the two groups was compared,as well as the pre-and post-treatment scores for subjective symptoms,meibomian opening status,meibomian gland secretion characteris-tics,Schirmer I test(SIT),corneal fluorescence staining(FLS),tear film breakup time(TBUT),tear interleukin-10(IL-10),tear interleukin-13(IL-13),fibroblast growth factor receptor 2(FGFR2)expression level and quality of life.The inci-dence of adverse reactions was recorded for both groups.Results Both groups had 2 dropouts.The total effective rate of treatment in the observation group[90.00%(36/40)]was higher than that in the control group[72.50%(29/40)],show-ing significant differences(P<0.05).At 4 and8 weeks after treatment,the SIT and tear film breakup time in the observation group were longer than those in the control group,while the subjective symptom scores,meibomian gland function scores,and FLS were lower than those in the control group(P<0.01).At 4 and 8 weeks after treatment,the expression levels of IL-10 and FGFR2 in tears in the observation group were higher than those in the control group,while the expression level of IL-13 was lower than that in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).At 8 and 12 weeks after treatment,the scores of the quality of life scale brief in the ob-servation group were higher than those in the control group(P<0.05).Conclusion The combination of Qiju Dihuang pills and meibomian gland massage and compression is safe and effective in the treatment of dry eye syndrome caused by MGD,which can inhibit inflammatory reactions,alleviate clinical symptoms,and enhance patients'quality of life.

关键词

睑板腺功能障碍/杞菊地黄丸/干眼病/按摩/角膜荧光染色评分/泪膜破裂时间/基础泪液分泌试验/成纤维细胞生长因子受体2

Key words

Meibomian gland dysfunction/Qiju Dihuang pills/Dry eye disease/Massage/Corneal fluorescence stai-ning score/Tear film breakup time/Schirmer Ⅰ test/Fibroblast growth factor receptor 2

引用本文复制引用

基金项目

2022年河北省中医药管理局中医药类指导性科研计划项目(2022563)

出版年

2024
临床误诊误治
解放军白求恩国际和平医院

临床误诊误治

CSTPCD
影响因子:0.914
ISSN:1002-3429
段落导航相关论文